sorafenib has been researched along with tanespimycin in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tanespimycin) | Trials (tanespimycin) | Recent Studies (post-2010) (tanespimycin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 921 | 39 | 496 |
| Protein | Taxonomy | sorafenib (IC50) | tanespimycin (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.004 | |
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 3 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 7.65 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.031 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.9391 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.5124 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 3 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.031 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.496 | |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | 0.78 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, C | 1 |
| Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Chen, R; Curley, SA; Liu, H; McConkey, DJ; Ward, JF; Zhang, T | 1 |
1 review(s) available for sorafenib and tanespimycin
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
1 trial(s) available for sorafenib and tanespimycin
| Article | Year |
|---|---|
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
2 other study(ies) available for sorafenib and tanespimycin
| Article | Year |
|---|---|
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53 | 2012 |